Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
about
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.A novel therapeutic effect of statins on nephrogenic diabetes insipidusOvercoming Challenges With Statin TherapySterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol statusCholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study)Safety of statins: an updateApproach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.Niacin or ezetimibe for patients with, or at risk of coronary heart diseaseRosuvastatin calcium in acute coronary syndromes.Statin-induced myopathy: the two faces of Janus.High-density lipoproteins and coronary artery disease: a single-center cohort study.No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis.Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.Approximate equivalent rosuvastatin doses for temporary statin interchange programs.Rosuvastatin for the treatment of hypercholesterolemia.Fibrates in combination with statins in the management of dyslipidemia.Rationale for intensive statin treatment in high-risk patients.Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?How safe is aggressive statin therapy?Review article: The role of statins in reducing perioperative cardiac risk: Physiologic and clinical perspectives.Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease.The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.Current Perspectives on rosuvastatin.Clinical efficacy and safety of statins in managing cardiovascular risk.The safety of rosuvastatin: effects on renal and hepatic function.Safety of statins.Clinical characterization and molecular mechanisms of statin myopathy.Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin.Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Drug safety evaluation of rosuvastatin.Increased expression of CD14 in macrophages after inhibition of the cholesterol biosynthetic pathway by lovastatin.Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.Rosuvastatin: achieving cholesterol targets.Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.Rosuvastatin (Crestor) and rhabdomyolysis.Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins?
P2860
Q24531203-B826BEA6-CE9D-420C-8B23-0E46D70A26B3Q27005638-DE496743-D855-4CC2-90B0-2012B761EF85Q28073319-029DBA2D-3521-46CA-9FA7-CA317E0F1E19Q28569337-F5FE7F96-3DBC-4FE3-B6CA-DF2C720D9869Q33590777-004CA756-A130-4832-837B-742DF499BD38Q33737675-0A57A7D9-A35D-4766-95D4-6735E07DF71FQ33949312-3397D796-8F3E-4967-8B57-34458E14D09DQ34156361-782C6458-9A18-4E14-9706-A4DEE819B40EQ34300722-5AE9FAD4-B5BF-4CBD-9D27-AA93F2BA5504Q34338367-623EC99A-609B-42C5-A7B6-DC6E00146086Q34554637-EC13B7B2-4AE9-4E0A-B494-2F65C7B520A4Q34992719-5C597352-6E29-4968-A6E0-B8F01A62C3F8Q35210176-B7D95FE7-763E-418B-B170-35E3F08F1A7AQ35605494-D86AADBC-AF6A-4AA9-830D-250F68E9124DQ35696163-EDBF9628-0C2C-4FB1-8C1A-003B6AD7833CQ35798817-FD772352-D860-4F8F-AD8B-5B9539973D99Q36188328-5CC6A961-C276-40C0-AF55-DE7FA483A1A9Q36366283-F18F4236-B020-49E4-9494-79135B4A4F75Q36444348-D105E68E-A3B0-45AC-A93F-87EEE8B4C564Q36577189-41404463-A1ED-4D22-9112-0DA3CE3093CAQ36587418-DBFA6C22-0BAC-48CF-BE8D-08C37076D217Q36641901-174E12A1-2DFF-4A67-BCA0-C38C9095F82FQ36752063-5D456A14-BFB0-4DDD-9966-E2475038F084Q36752067-82C6860A-A26E-4F60-B835-B43A43B38896Q36796490-99504E84-5164-4434-9D1B-A812FE2D4E9DQ36812806-1752E0B5-910C-48A4-BFF3-C0EE74B81CB6Q36945023-73524CC6-F5BB-42D1-98FF-7E7FB31B5841Q37095088-AA8FDD7C-9322-436E-8A4E-B066270684EDQ37230383-7A3966E5-1A16-454F-9C41-459A2DF0E25AQ37388209-012FDE41-44C4-4861-95FD-5A56B524AB44Q37855316-28B9157C-EE6D-4CD1-A258-72744EDEE360Q37855801-C70F8DE3-7E37-47DC-925B-8DF2C52C89B8Q37945657-3B5AE6E7-B3B5-4CF4-A528-8E2D09BFD42EQ40068676-3F18CB55-244F-493C-AAE4-E46680E856FFQ40164897-0E3AE0DE-073D-4E11-A070-3D264E34F430Q40426760-DEA47E86-3CAA-4557-AEBE-05142A5CA254Q40434790-AE14950E-AA72-4A40-8F91-9C2F519E5AD4Q41066037-7F18851B-9C2F-453C-B948-B4E344CEDC06Q42599205-F43C2207-12C1-4EE8-B703-ED908EB8EB70Q42936079-C5F9BF86-F61C-4149-B87D-E39AA49B5102
P2860
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@ast
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@en
type
label
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@ast
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@en
prefLabel
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@ast
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@en
P1476
Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams.
@en
P2093
H Bryan Brewer
P304
P356
10.1016/S0002-9149(03)00779-3
P407
P577
2003-08-01T00:00:00Z